ROCKVILLE, Md.--(BUSINESS WIRE)--
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty
pharmaceutical company, today announced that the Company's management
will provide a business update on the Company at the Cowen and Company
Healthcare Conference.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Presentation Date: Monday, March 3
|
|
|
|
|
|
|
|
|
|
|
|
|
Time: 1:30pm ET
|
|
|
|
|
|
|
|
|
|
|
|
|
Place: The Boston Marriott Copley Place Hotel, Boston, MA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on developing and commercializing products for the treatment of
central nervous system, or CNS, diseases. The Company has two marketed
products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and
Trokendi XR™ (extended-release topiramate). The Company is also
developing several product candidates in psychiatry to address large
market opportunities in ADHD, including ADHD patients with impulsive
aggression. These product candidates include SPN-810 for impulsive
aggression in ADHD and SPN-812 for ADHD.
Supernus Pharmaceuticals, Inc.
Jack A. Khattar, President and CEO
or
Gregory
S. Patrick, Vice President and CFO
301-838-2591
or
Investor
Contact:
Cockrell Group, 877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
Source: Supernus Pharmaceuticals, Inc.
News Provided by Acquire Media